Prot #CA209649: A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab or Nivolumab in Combination with Oxaliplatin Plus Fluoropyrimidine versus Oxaliplatin plus Fluoropyrimidine in Subjects with Previously Untreated Advanced or

Project: Research project

Project Details

StatusActive
Effective start/end date6/13/17 → 6/13/24

Funding

  • Bristol-Myers Squibb Company (Prot #CA209649)